Dear all, To answer directly to the question of capripoxvirus recombinant vaccine approach developed by CIRAD, we have generated H-PPR and F-PPR recombinant capripoxviruses that protect against both diseases. We also generated recombinant Rift Valley fever-capripoxvirus that is imunologically active (no challenge studies so far). We are thinking about a trivalent vaccine, for instance PPR-Rift-capripoxvirus. The advantages of the capripoxvirus in our hands are: - easy platform to insert and express in target animals several different transgenes (e.g.: a perfectly characterized immunogen of Brucella could be inserted and tested) - long lasting immunity after one shoot (at least one year of protection) - DIVA property for the diseases targeted by the inserts (in the case of PPR, we induce anti-H or anti-F immune responses and we test the serum anti-N antibodies by a commercial ELISA) - thermal stability (2 weeks in liquid form at +36°C) However, the current drawbacks are: - validations are still required before use in the field: purity check (possibly by deep sequencing without a priori), upscaling of the production, etc... (according to the requirements of the private industry and international regulations) - pre-immunity interference with the vaccine: first vaccination with this type of vaccine in a ruminant population infected by wild-type capripoxvirus may not protect more than 50% of the animals against pox _AND_ PPR. This means that the first year, a combination of recombinant capripox and Nigeria75/1 vaccine [a paper in Vaccine (Chaudary et al, 2009) showed that both vaccines could be combined in a single injection] should be applied to reduce the prevalence of capripoxvirus and then the next year, only the recombinant capripoxvirus could be used - Lack of funds to speed up finalization of laboratory work before transfer of the vaccine to the private sector Regards For CIRAD, Emmanuel Albina Le 25/02/2014 12:19, Paul Rossiter a écrit : > Dear moderator and dear all, > I agree with that we should include other diseases such as sheep and > goats pox in the progressive control of PPR in small ruminants. If I > well remember Cirad had in collaboration with LANAVET > (Cameroon) developped recombinant vaccine against PPR using Capripox > as support. I don't know if this vaccine is still available ; if yes > so we can easily go for progressive control of PPR and SGP. I think Dr > Adama or Ngagnou could answer to this. > Kind regards! > Bidjeh Kebkiba, > Head of virology Unit, IRED (Chad), > Route de farcha, > PO box 433, Ndjamena- Chad. > > ------------------------------------------------------------------------ > > To unsubscribe from the FAO-AnimalHealth-L list, click the following link: > https://listserv.fao.org/cgi-bin/wa?SUBED1=FAO-AnimalHealth-L&A=1 > -- Signature electronique ######################################################################## To unsubscribe from the FAO-AnimalHealth-L list, click the following link: https://listserv.fao.org/cgi-bin/wa?SUBED1=FAO-AnimalHealth-L&A=1